Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity
Open Access
- 25 November 2025
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 193, 118820
Abstract
No abstract availableKeywords
Funding Information
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Mahidol University
- National Research Council of Thailand
This publication has 54 references indexed in Scilit:
- Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myelomaClinical and Experimental Medicine, 2024
- Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myelomaBiomedicine & Pharmacotherapy, 2023
- Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumorsMolecular Therapy, 2022
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studyThe Lancet, 2021
- GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interactionTranslational Oncology, 2021
- Immuno-oncologic Approaches: CAR-T Cells and Checkpoint InhibitorsClinical Lymphoma Myeloma and Leukemia, 2017
- Structure and T Cell Inhibition Properties of B7 Family Member, B7-H3Structure, 2013
- B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interactionEuropean Journal of Immunology, 2009
- Multiple myelomaThe Lancet, 2009
- Cell Surface Molecules and Early Events Involved in Human T Lymphocyte Activation1987